Review
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. May 15, 2014; 6(5): 129-138
Published online May 15, 2014. doi: 10.4251/wjgo.v6.i5.129
Modulators affecting the immune dialogue between human immune and colon cancer cells
Meir Djaldetti, Hanna Bessler
Meir Djaldetti, Hanna Bessler, The Laboratory for Immunology and Hematology Research, Rabin Medical Center, Hasharon Hospital, 49372 Petah-Tiqva, Israel
Meir Djaldetti, Hanna Bessler, The Sackler School of Medicine, Tel-Aviv University, 699780 Ramat-Aviv, Israel
Author contributions: Djaldetti M and Bessler H contributed equally to this work.
Correspondence to: Meir Djaldetti, MD, Professor of Medicine, The Laboratory for Immunology and Hematology Research, Rabin Medical Center, Hasharon Hospital, 7 Keren Kayemet St., 49372 Petah-Tiqva, Israel. meird@clalit.org.il
Telephone: +972-3-9372397 Fax: +972-3-9372398
Received: November 24, 2013
Revised: January 3, 2014
Accepted: April 11, 2014
Published online: May 15, 2014
Core Tip

Core tip: The substantial number of studies that soundly demonstrated the close relationship between chronic inflammation and colon carcinogenesis has encouraged researchers to investigate the pathways interrelated with this process. The results point-out to various factors, molecules and genes that may jointly enhance or inhibit tumor development. The close linkage between immune and colon cancer cells resulting in a cross-talk between them with a consequent equilibrium in inflammatory cytokines release opens a new window for understanding the complicated stages of cancer initiation and progression. Moreover, the capability of emerging modulators to target the dialogue between immune and cancer cells indicates that immunomodulation may serve as a promising addition to the drug armamentarium for colorectal cancer.